Home > Oncology > SABCS 2021 > Early-Stage Breast Cancer > Concurrent taxane plus anthracycline most beneficial in reducing risk of breast cancer

Concurrent taxane plus anthracycline most beneficial in reducing risk of breast cancer

Presented By
Dr Jeremy Braybrooke, University Hospitals Bristol NHS Foundation Trust, UK

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
SABCS 2021
A meta-analysis based on data of 18,203 early-stage breast cancer patients demonstrated anthracycline plus taxane to reduce the risk of breast cancer recurrence by 15% compared with taxane alone. The treatment did not significantly increase number of deaths from cardiovascular disease or leukaemia. Anthracycline-containing and taxane-containing chemotherapy regimens reduce the rate of early-stage breast cancer recurrence by about a third compared with no chemotherapy. However, concerns about the increased risks of cardiac toxicity and leukaemia have resulted in treatment regimens without anthracycline. To better characterise the benefits and risks of anthracycline and taxane chemotherapy in early-stage breast cancer patients, a meta-analysis was performed based on individual data of 18,203 participants from 16 randomised-controlled trials starting before 2010. All trials included at least 6 cycles of chemotherapy in each arm. Primary outcomes were recurren...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on